联芳基氨基噻嗪类BACE1抑制剂的3D-QSAR分析与分子对接研究

被引：1

作者：

刘景陶 ^{[1
]}

倪敬轩 ^{[2
]}

王晓 ^{[2
]}

毕毅 ^{[2
]}

机构：

[1] 河套学院理学系

[2] 烟台大学药学院

来源：

中国药房 | 2018年 / 29卷 / 10期

关键词：

联芳基氨基噻嗪类; β-淀粉样前体蛋白水解酶; 抑制剂; 三维定量构效关系; 分子对接;

D O I：

暂无

中图分类号：

R914 [药物化学];

学科分类号：

100705 [微生物与生化药学];

摘要：

目的:为新型高效联芳基氨基噻嗪类β-淀粉样前体蛋白水解酶1（BACE1）抑制剂的设计合成与新型AD治疗药物研发提供理论基础。方法:选取41个联芳基氨基噻嗪类BACE1抑制剂分子,运用SYBYL-X 2.0软件包,以比较分子场分析法（CoMFA）与比较分子相似性指数分析法（CoMSIA）构建该类衍生化合物的三维定量构效关系（3D-QSAR）模型,并以Surflex-dock分子对接方法分析该类化合物与BACE1的结合模式。结果:以CoMFA法和CoMSIA法构建的3D-QSAR模型的交叉验证系数（q2）均大于0.5,表明其预测能力良好;所建三维等势图能直观反映不同位置引入取代基对化合物活性的影响。Surflex-dock对接分析显示,联芳基氨基噻嗪类分子与BACE1中的ASP80、ASP276、TYR246等氨基酸残基具有氢键作用。结论:基于联芳基氨基噻嗪类衍生化合物所构建的3D-QSAR模型具有良好的预测能力,可指导该类化合物的结构优化;TYR246可能是联芳基氨基噻嗪类抑制剂化合物分子与BACE1结合的另一潜在活性功能残基。通过3D-QSAR分析与分子对接,可进行新型高效联芳基氨基噻嗪类BACE1抑制剂的设计合成,进而用于研发新型AD治疗药物。

引用

页码：1335 / 1339

页数：5

共 11 条

[1]

非肽类β-分泌酶1(BACE1)抑制剂的研究进展 [J].

李慧宁 ;

李凤然 ;

程卯生 ;

刘洋 .

中国药物化学杂志, 2016, 26 (06) :498-508

[2]

A REVIEW ON ALZHIMER’S DISEASE: PATHOLOGY; MOLECULAR CONDITIONS; MANAGEMNT AND CAUSES.[J].Vinayaga Moorthi;Preethi B.Asian Journal of Pharmaceutical and Clinical Research.2017, 5

[3]

3D QSAR studies; pharmacophore modeling; and virtual screening of diarylpyrazole–benzenesulfonamide derivatives as a template to obtain new inhibitors; using human carbonic anhydrase II as a model protein.[J].Yeganeh Entezari Heravi;Hassan Sereshti;Ali Akbar Saboury;Jahan Ghasemi;Marzieh Amirmostofian;Claudiu T. Supuran.Journal of Enzyme Inhibition and Medicinal Chemis.2017, 1

[4]

3D-QSAR, molecular dynamics simulations and molecular docking studies of benzoxazepine moiety as mTOR inhibitor for the treatment of lung cancer [J].

Chaube, Udit ;

Chhatbar, Dhara ;

Bhatt, Hardik .

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2016, 26 (03) :864-874

[5]

3D-QSAR (CoMFA; CoMFA-RG; CoMSIA) and molecular docking study of thienopyrimidine and thienopyridine derivatives to explore structural requirements for aurora-B kinase inhibition.[J].Ankit Borisa;Hardik Bhatt.European Journal of Pharmaceutical Sciences.2015,

[6]

Development of 2-aminooxazoline 3-azaxanthenes as orally efficacious β-secretase inhibitors for the potential treatment of Alzheimer's disease [J].

Chen, Jian Jeffrey ;

Liu, Qingyian ;

Yuan, Chester ;

Gore, Vijay ;

Lopez, Patricia ;

Ma, Vu ;

Amegadzie, Albert ;

Qian, Wenyuan ;

Judd, Ted C. ;

Minatti, Ana E. ;

Brown, James ;

Cheng, Yuan ;

Xue, May ;

Zhong, Wenge ;

Dineen, Thomas A. ;

Epstein, Oleg ;

Human, Jason ;

Kreiman, Charles ;

Marx, Isaac ;

Weiss, Matthew M. ;

Hitchcock, Stephen A. ;

Powers, Timothy S. ;

Chen, Kui ;

Wen, Paul H. ;

Whittington, Douglas A. ;

Cheng, Alan C. ;

Bartberger, Michael D. ;

Hickman, Dean ;

Werner, Jonathan A. ;

Vargas, Hugo M. ;

Everds, Nancy E. ;

Vonderfecht, Steven L. ;

Dunn, Robert T., II ;

Wood, Stephen ;

Fremeau, Robert T., Jr. ;

White, Ryan D. ;

Patel, Vinod F. .

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2015, 25 (04) :767-774

[7]

Variational principles for mechanistic quantitative structure-activity relationship (QSAR) studies: application on uracil derivatives' anti-HIV action [J].

Putz, Mihai V. ;

Dudas, Nicoleta A. .

STRUCTURAL CHEMISTRY, 2013, 24 (06) :1873-1893

[8]

Binding conformations, QSAR, and molecular design of Alkene-3-quinolinecarbonitriles as Src inhibitors [J].

Zeng, G. H. ;

Fang, D. Q. ;

Wu, W. J. ;

Zhang, R. ;

Xie, W. G. ;

Wu, J. H. ;

Shen, Y. .

INTERNATIONAL JOURNAL OF QUANTUM CHEMISTRY, 2013, 113 (10) :1467-1478

[9]

Receptor-guided 3D-QSAR approach for the discovery of c-kit tyrosine kinase inhibitors [J].

Almerico, Anna Maria ;

Tutone, Marco ;

Lauria, Antonino .

JOURNAL OF MOLECULAR MODELING, 2012, 18 (07) :2885-2895

[10]

Three‐dimensional Quantitative Structure–activity Relationship Modeling of γ‐Secretase Inhibitors using Molecular Field Analysis.[J].TarnvirSammi;OmSilakari;MuttineniRavikumar.Chemical Biology & Drug Design.2008, 2

← 1 2 →